In this study, we show that baseline, 12 weeks HBsAg and the presence of cirrhosis were significant factors affecting the course of IFN treatment, and both were risk factors (β=7.27,4.27,10.91; p<0.05). Here, IFNA1 is linked to Cirrhosis.